Corpus Intelligence IC Memo — LINCOLN REGIONAL CENTER 2026-04-26 09:37 UTC
IC Memo — LINCOLN REGIONAL CENTER
Investment Committee Memorandum | NE | 248 beds | Grade C | EBITDA uplift $3.4M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LINCOLN REGIONAL CENTER

CCN 284003 | nan, NE | 248 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LINCOLN REGIONAL CENTER is a 248-bed under-performing / distressed in nan, NE with $46.7M in net patient revenue and a -53.3% operating margin. The hospital serves a payer mix of 0.2% Medicare, 7.0% Medicaid, and 92.7% commercial.

Thesis: Undervalued. Our ML models identify $3.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -53.3% to -45.9% (+736bps).

Net Revenue HCRIS$46.7M
Current EBITDA COMPUTED$-24.9M
Operating Margin COMPUTED-53.3%
Occupancy HCRIS79.7%
Revenue / Bed COMPUTED$188K
Net-to-Gross HCRIS100.0%
Distress Probability ML50.6%

2. Market Context & Competitive Position

98
NE Hospitals
-6.3%
State Median Margin
1689
Comparable Hospitals

NE has 98 Medicare-certified hospitals with a median operating margin of -6.3%. The target's margin of -53.3% places it below the state median. Among 1689 size-comparable peers (124-496 beds), the median margin is -3.9%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (124-496), prioritizing same-state peers. 1689 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LINCOLN REGIONAL CENTER (Target)NE248$46.7M-53.3%
RONALD REAGAN UCLACA446$2.62B-6.8%
LUCILE PACKARD CHILDRENS HOSPICA394$2.39B-0.8%
MAYO CLINIC HOSPITALAZ315$2.25B1.4%
RAINBOW BABIES & CHILDRENS HOSOH231$2.22B-5.0%
EASTERN MAINE MEDICAL CENTERME352$2.05B48.1%
ARTHUR G JAMES CANCER HOSPITALOH356$1.95B21.0%
MOFFITT CANCER CENTERFL218$1.91B16.0%
UCI MEDICAL CENTERCA397$1.90B-2.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.4M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$981K+210bp18mo
Cost to Collect4.5%2.5%$934K+200bp12mo
Denial Rate Reduction12.0%6.5%$925K+198bp12mo
A/R Days Reduction5200.0%3800.0%$568K+122bp9mo
Clean Claim Rate88.0%96.0%$30K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$981K
Cost to Collect
$934K
Denial Rate Reduction
$925K
A/R Days Reduction
$568K
Clean Claim Rate
$30K
Total EBITDA Uplift$3.4M
Current EBITDA$-24.9M
+ RCM Uplift+$3.4M
Pro Forma EBITDA$-21.5M
Current Margin-53.3%
Pro Forma Margin-45.9%
WC Released (1x)$1.8M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-38.3M$-129.9M0.00x-100.0%
Base (11x exit)10.0x11.0x$-38.3M$-155.3M0.00x-100.0%
Bull Case9.0x11.0x$-34.5M$-156.4M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-34.5M$-180.8M0.00x-100.0%
Bear Case11.0x10.0x$-42.1M$-134.6M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-42.1M$-161.8M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
HighElevated distress probabilityModel estimates 50.6% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 1689 hospitals with 124-496 beds
  • Same-state prioritization (n=8)
  • Comp margins: P25=-13.6% / P50=-3.9% / P75=5.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.